---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-049988"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2024-04-22T23:59:59+00:00"
generated_at: "2026-06-03T14:29:32.974925+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# ArriVent BioPharma appoints Kristine Peterson to Board of Directors

## Summary
- Appointment effective April 20, 2024; Peterson to serve as Class III Director until 2027 annual meeting.
- Peterson brings over 30 years' experience; former CEO of Valeritas and executive at J&J and Bristol-Myers Squibb.
- Receives non‑employee director compensation: annual cash retainer of $45,000 and stock option with $235,000 grant date fair value.
- Option vests one year from grant date (April 22, 2024); no related transactions or family relations disclosed.
- Board determined she is independent under Nasdaq rules; no committee assignments yet.

## SEC filing metadata
- accession: 0001104659-24-049988
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2024-04-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465924049988/0001104659-24-049988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465924049988/tm2412347d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-049988
- JSON: https://secwatch.observer/filing/0001104659-24-049988.json
- Plain text: https://secwatch.observer/filing/0001104659-24-049988.txt

## Key facts
- Executive change
  Kristine Peterson was appointed as Director at ArriVent BioPharma, Inc..
  - Action: appointed
  - Role: Director
  source text: On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1868279/000110465924049988/0001104659-24-049988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.